Protocol

HOD1221: A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma (AHOD1221)

Diseases

Leukemias / Lymphomas : Relapsed or Refractory Hodgkin Lymphoma

Description

This part of the study is the Phase 1 of a 2 phase study of the combination of the drug brentuximab vedotin with the drug gemcitabine. This is called a Phase 1 study because the goal is to find the highest dose of brentuximab vedotin that we can give safely when it is used together with gemcitabine. Brentuximab vedotin has been approved by the FDA for the treatment of adults with Hodgkin lymphoma, when other treatments have been tried and are no longer working. It has been shown to be well-tolerated without a lot of side effects in adults.

Phase 2 of the study will evaluate the response rate in patients with Hodgkin lymphoma to the combination of the drug brentuximab vedotin with the drug gemcitabine at the dose defined in phase 1.


Objectives


Eligibility Criteria, among others, include:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE(1-866-278-5833).


Contact

Monika Metzger, MD, MSc
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.